A Phase 1 Study of Lirilumab (Antibody Against Killer Immunoglobulin-Like Receptor Antibody KIR2D; IPH2102) in Patients With Solid Tumors and Hematologic Malignancies

Oncotarget - United States
doi 10.18632/oncotarget.24832
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2017English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors

Investigational New Drugs
OncologyPharmacology
2016English

A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors

Investigational New Drugs
OncologyPharmacology
2014English

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies

Cancer
Cancer ResearchOncology
2015English

Phase I Study of GSK461364, a Specific and Competitive Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2011English

Phase I Study of Tomuzotuximab, a Glycoengineered Therapeutic Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Carcinomas

ESMO Open
Cancer ResearchOncology
2018English

A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy